ADAM17 and metabolic dysfunction-associated steatohepatitis: Due to RECK’s inhibition of ADAM17 and consequent downregulation in EGFR signaling, it is plausible that sustaining or inducing RECK has the potential to prevent or even reverse hepatic fibrosis seen in NASH.